Login to Your Account

Going Beyond Linaclotide

Ironwood Licenses CNS Drug In $345M Deal with Bionomics

By Jennifer Boggs
Managing Editor

Friday, January 6, 2012

Proving that Ironwood Pharmaceuticals Inc. seeks to grow its pipeline beyond promising irritable bowel syndrome drug linaclotide, the Cambridge, Mass.-based firm picked up rights to a Phase I-stage anti-anxiety compound from Bionomics Ltd. in a deal valued at up to $345 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription